BRAF V600 | ApexOnco - Clinical Trials news and analysis

x

“I am very impressed - it has become my go-to platform”

Chief Business Officer

US public biotech company

Click here for more information

Conferences Trial results

13 September 2024

ESMO 2024 – degraders disappoint again

Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.

Subscribe to BRAF V600